GLP-1 RAs May Ease Psoriasis, PsA Data Limited

Published evidence linked liraglutide and semaglutide to improvements in psoriasis severity, inflammatory markers, and metabolic outcomes, while evidence in psoriatic arthritis remained sparse.

By
Andrea Surnit
June 27, 2026
4 min

Conexiant

Overview

Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) may improve psoriasis severity and metabolic markers, though evidence for their use in psoriatic arthritis (PsA) is limited.

Background

Psoriasis and psoriatic arthritis are chronic inflammatory conditions often associated with metabolic comorbidities. The exploration of GLP-1 RAs as a treatment option is significant due to their potential benefits in managing skin and metabolic health. However, the current evidence base remains insufficient to warrant changes in clinical practice.

Data Highlights

No systematic numerical data provided in the source material.

Key Findings

GLP-1 RAs like liraglutide and semaglutide are associated with improvements in Psoriasis Area and Severity Index (PASI) scores.
Reductions in inflammatory markers such as IL-17, IL-23, and TNF-alpha were observed in patients treated with liraglutide.
Improvements in psoriasis severity were noted alongside reductions in body mass index and waist circumference.
Evidence for GLP-1 RAs in PsA is limited, with only a few open-label trials reporting improvements in disease activity.
Some benefits of GLP-1 RAs may occur independently of weight loss, suggesting a direct immunomodulatory effect.

Clinical Implications

Clinicians should consider the potential of GLP-1 RAs in managing psoriasis, particularly in patients with obesity or metabolic syndrome. However, the limited evidence for their efficacy in psoriatic arthritis necessitates cautious interpretation of these findings.